Company intelligence / Profile preview

MimeCure

Ownership: Private
Development stage: Preclinical

Overview

MimeCure's lead compound MC002, an active fragment of mimecan (osteoglycin), shows strong preclinical evidence of promoting alveolar epithelial regeneration and repair in COPD models, with initial in vivo results indicating potential to restore lung function and reverse tissue damage. Phase 1 clinical trials are planned but have not yet started[4][2].

Therapeutic areas: Pulmonology
Modalities: ProteinBiologic
Industry: Biotech

Drug pipeline

1 asset

MC002

Pre-clinical

Indications: Chronic Obstructive Pulmonary Disease

Partnerships

University of GroningenPharma Connect CapitalBiotech BoosterBusiness Generator Groningen

Beyond the preview

Go deeper on MimeCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MimeCure.

Explore the full profile